WATCH LIVE as Gambakwe looks at the revelations by Jelous Mawarire that there is a potential legal loophole regarding presidential term limits. His argument is that there is a plan to change the constitution before 4 September 2026 so that the period served from 4 September 2023 to 4 September 2026 is legally interpreted as being “2 years and 363 days”—or effectively less than a full 3-year period. This interpretation would theoretically allow the argument that this time does not count as a full “term,” thereby enabling the president to be eligible for re-election.
Key Events For Today
ZANU-PF cell day held
Top Trending News
1. Jelous Mawarire explains the two coups that have taken place in Zimbabwe
2. Agency Gumbo explain the upcoming ammendments
3. Tanaka Manjengwa has died
4. Anesu Mwarianesu attending UFI services
Business
UK Based man Prince Abraham loses $700 000 to fugitive Zimbabweans who have since fled Zimbabwe in 2018. The amount was stolen by Delny Deanna Ashley Davies.
Africa
1. Motsepe demands R83 Million from Botswana. Bridgette Motsepe-Radebe was exonerated by the Botswana High Court in a case known as the “Butterfly Case.”
The court found that allegations from 2019—accusing her of involvement in a $10-billion money-laundering conspiracy to destabilize Botswana’s government—were “unlawful, false, and reckless.” An independent investigation termed them a “clumsy hoax.” In a June 2025 consent order, Motsepe-Radebe abandoned her claim for personal damages, but the state was found liable for her reasonable legal costs and expenses for vindicating her reputation. Motsepe-Radebe’s legal team is demanding payment of 68 million pula (approximately R83 million) for these costs.
The Botswana government admits it is legally obliged to pay but states compliance has so far been only “partial,” citing logistical and financial constraints.
Her lawyers accuse the government of being in contempt of court for failing to pay and for delaying required apology advertisements. The government confirms apology ads are booked for February 2026 in some outlets (Sunday Times, SABC), but key international placements (Financial Times, CNN, Wall Street Journal) are still outstanding, long past the court-ordered seven-day deadline. At the time, the South African businesswoman Bridgette Motsepe-Radebe was reported to have been fingered as a co-signatory to at least two bank accounts holding some of the more than $10 billion (R150 billion) allegedly stolen from the Botswana government to finance “terrorism”.
Community
Mve valentine’s day promotion
Notes
2. The BRILLIANT 011 clinical trial is a groundbreaking, first-in-human HIV vaccine study launched in South Africa in late January 2026. Led by the South African Medical Research Council (SAMRC), it represents a significant milestone in African-led medical research. The trial nearly collapsed in 2025 due to massive U.S. funding cuts to USAID programs. It was revived through emergency funding from the Bill & Melinda Gates Foundation and the SAMRC, allowing it to proceed in a streamlined, African-led format. The project is part of the BRILLIANT Consortium, a group of researchers from eight African nations, notably led by prominent African women scientists like Professor Glenda Gray. The first volunteer was successfully enrolled during the week of January 19, 2026. Participants will be monitored for 12 months to assess how their immune systems react to the vaccine “cocktail”. Zimbabwe and Zambia are part of the eight-country BRILLIANT Consortium, which also includes Nigeria, Uganda, Kenya, Tanzania, and Mozambique. IAVI C114 Trial: This Phase 1 HIV vaccine trial, sponsored by IAVI, is being conducted at the Mutala Trust Clinical Trial Site in Harare, Zimbabwe.
Trial Size: The IAVI trial aims to enroll approximately 120 healthy adults across its sites in Zimbabwe and South Africa. The IAVI C114 trial is a Phase 1 clinical study launched in August 2025 to evaluate a novel HIV vaccine candidate called GRAdHIVNE1. It is notable for being co-led by African researchers and conducted across sites in Zimbabwe and South Africa. The trial tests GRAdHIVNE1, which uses a gorilla adenovirus vector. It is a T-cell inducing vaccine designed to target “highly networked” parts of the virus that are less likely to mutate. This includes 48 people living with HIV who are virally suppressed on antiretroviral therapy (ART) to see if the vaccine can work as a therapeutic tool. Participants are monitored for 19 months to assess safety and the strength of the immune response. The first dose was administered on July 28, 2025, in Harare.
